PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.02%
Revenue growth under 50% of MCHP's 4.63%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
-3.26%
Negative gross profit growth while MCHP is at 5.21%. Joel Greenblatt would examine cost competitiveness or demand decline.
-3.40%
Negative EBIT growth while MCHP is at 8.35%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-4.06%
Negative operating income growth while MCHP is at 7.48%. Joel Greenblatt would press for urgent turnaround measures.
-0.75%
Negative net income growth while MCHP stands at 6.24%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-0.53%
Negative EPS growth while MCHP is at 7.07%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-1.07%
Negative diluted EPS growth while MCHP is at 6.12%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.09%
Dividend growth under 50% of MCHP's 9.00%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
38.46%
OCF growth at 50-75% of MCHP's 61.11%. Martin Whitman would question if the firm lags in monetizing sales effectively.
1040.43%
FCF growth above 1.5x MCHP's 66.44%. David Dodd would verify if the firm’s strategic investments yield superior returns.
68.63%
10Y revenue/share CAGR under 50% of MCHP's 270.17%. Michael Burry would suspect a lasting competitive disadvantage.
13.51%
5Y revenue/share CAGR under 50% of MCHP's 86.00%. Michael Burry would suspect a significant competitive gap or product weakness.
19.91%
3Y revenue/share CAGR under 50% of MCHP's 46.77%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
103.13%
10Y OCF/share CAGR under 50% of MCHP's 603.82%. Michael Burry would worry about a persistent underperformance in cash creation.
-1.85%
Negative 5Y OCF/share CAGR while MCHP is at 198.51%. Joel Greenblatt would question the firm’s operational model or cost structure.
35.56%
3Y OCF/share CAGR under 50% of MCHP's 181.46%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
227.96%
Below 50% of MCHP's 3949.90%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
16.17%
Below 50% of MCHP's 297.03%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
27.56%
Below 50% of MCHP's 62.48%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
81.65%
10Y equity/share CAGR at 50-75% of MCHP's 132.53%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
68.77%
5Y equity/share CAGR is in line with MCHP's 68.94%. Walter Schloss would see parallel mid-term profitability and retention policies.
101.75%
Positive short-term equity growth while MCHP is negative. John Neff sees a strong advantage in near-term net worth buildup.
341.28%
10Y dividend/share CAGR above 1.5x MCHP's 86.34%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
99.61%
5Y dividend/share CAGR 1.25-1.5x MCHP's 80.83%. Bruce Berkowitz verifies that high dividend hikes remain sustainable, not a sign of over-distribution.
37.84%
Below 50% of MCHP's 79.08%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
1.02%
AR growth is negative/stable vs. MCHP's 3.69%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
4.80%
Inventory shrinking or stable vs. MCHP's 13.11%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
2.26%
Positive asset growth while MCHP is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
4.34%
1.25-1.5x MCHP's 3.85%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
0.03%
We have some new debt while MCHP reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-1.26%
Our R&D shrinks while MCHP invests at 5.14%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.95%
We cut SG&A while MCHP invests at 0.25%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.